Targeted therapies in bladder cancer: an overview of in vivo research

摘要: Survival of patients with muscle-invasive bladder cancer is poor and new therapies are needed. Currently, none the targeted agents that approved for therapy have been treatment few clinical trials performed had limited success, often owing to a lack efficacy toxic effects. However, many other novel investigated in animal models cancer. EGFR, FGFR-3, VEGF, mTOR, STAT3, androgen receptor CD24 molecular targets could be efficiently inhibited, resulting reduced tumour growth, multiple independent studies. Several targets, example COX-2, IL-12, Bcl-xL, livin choline kinase α, also observed inhibit but these findings not replicated date. Limitations several studies include use cell lines mutations downstream target, providing resistance tested therapy. Furthermore, certain technologies, such as interfering RNAs, although effective vitro, yet ready applications. Further preclinical research needed discover evaluate possible validated now available studied trials.